MicroRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism

Sachin Hajarnis, Ronak Lakhia, Matanel Yheskel, Darren Williams, Mehran Sorourian, Xueqing Liu, Karam Aboudehen, Shanrong Zhang, Kara Kersjes, Ryan Galasso, Jian Li, Vivek Kaimal, Steven Lockton, Scott Davis, Andrea Flaten, Joshua A. Johnson, William L. Holland, Christine M. Kusminski, Philipp E. Scherer, Peter C. HarrisMarie Trudel, Darren P. Wallace, Peter Igarashi, Edmund C. Lee, John R. Androsavich, Vishal Patel

Research output: Contribution to journalArticlepeer-review

140 Scopus citations


Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of renal failure. Here we identify miR-17 as a target for the treatment of ADPKD. We report that miR-17 is induced in kidney cysts of mouse and human ADPKD. Genetic deletion of the miR-17 ∼ 492 cluster inhibits cyst proliferation and PKD progression in four orthologous, including two long-lived, mouse models of ADPKD. Anti-miR-17 treatment attenuates cyst growth in short-term and long-term PKD mouse models. miR-17 inhibition also suppresses proliferation and cyst growth of primary ADPKD cysts cultures derived from multiple human donors. Mechanistically, c-Myc upregulates miR-17 ∼ 92 in cystic kidneys, which in turn aggravates cyst growth by inhibiting oxidative phosphorylation and stimulating proliferation through direct repression of Pparα. Thus, miR-17 family is a promising drug target for ADPKD, and miR-17-mediated inhibition of mitochondrial metabolism represents a potential new mechanism for ADPKD progression.

Original languageEnglish (US)
Article number14395
JournalNature communications
StatePublished - Feb 16 2017

Bibliographical note

Publisher Copyright:
© 2017 The Author(s).


Dive into the research topics of 'MicroRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism'. Together they form a unique fingerprint.

Cite this